Curanex Pharmaceuticals Inc CURX
is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to
treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients'
lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines
for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D | $3.0M | — | — |
| SG&A | $1.3M | $290.4K | — |
| Total operating expenses | $4.2M | $365.1K | — |
| Operating income | -$4.2M | -$365.1K | — |
| Interest expense | $8.5K | — | — |
| Net income | -$4.2M | -$361.5K | — |
| EPS, basic | -0.17 | -0.03 | — |
| EPS, diluted | -0.17 | -0.03 | — |
| Shares, diluted (wtd. avg.) | $25.5M | $13.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | $5.0M | — | — |
| Total current assets | $11.2M | $517.9K | — |
| Total assets | $11.6M | $517.9K | — |
| Accounts payable | $2.4K | $5.0K | — |
| Total current liabilities | $137.0K | $14.6K | — |
| Total liabilities | $361.0K | $14.6K | — |
| Retained earnings | -$4.8M | -$622.4K | — |
| Total equity | $11.2M | $503.4K | $60.1K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | -$10.5M | -$555.6K | — |
| Financing cash flow | $15.3M | $630.1K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-013677.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |